JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabt… Read more
JW (Cayman) Therapeutics Co. Ltd (JWCTF) - Total Assets
Latest total assets as of June 2025: $1.42 Billion USD
Based on the latest financial reports, JW (Cayman) Therapeutics Co. Ltd (JWCTF) holds total assets worth $1.42 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
JW (Cayman) Therapeutics Co. Ltd - Total Assets Trend (2018–2024)
This chart illustrates how JW (Cayman) Therapeutics Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
JW (Cayman) Therapeutics Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
JW (Cayman) Therapeutics Co. Ltd's total assets of $1.42 Billion consist of 48.1% current assets and 51.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $31.26 Million | 1.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $590.15 Million | 35.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how JW (Cayman) Therapeutics Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: JW (Cayman) Therapeutics Co. Ltd's current assets represent 48.1% of total assets in 2024, a decrease from 50.3% in 2018.
- Cash Position: Cash and equivalents constituted 45.1% of total assets in 2024, up from 39.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, an increase from 23.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 35.1% of total assets.
JW (Cayman) Therapeutics Co. Ltd Competitors by Total Assets
Key competitors of JW (Cayman) Therapeutics Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
JW (Cayman) Therapeutics Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - JW (Cayman) Therapeutics Co. Ltd generates 0.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - JW (Cayman) Therapeutics Co. Ltd is currently not profitable relative to its asset base.
JW (Cayman) Therapeutics Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 2.92 | 11.17 |
| Quick Ratio | 1.45 | 2.76 | 11.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $276.70 Million | $ 620.94 Million | $ 2.41 Billion |
JW (Cayman) Therapeutics Co. Ltd - Advanced Valuation Insights
This section examines the relationship between JW (Cayman) Therapeutics Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.97 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -21.7% |
| Total Assets | $1.68 Billion |
| Market Capitalization | $51.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values JW (Cayman) Therapeutics Co. Ltd's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: JW (Cayman) Therapeutics Co. Ltd's assets decreased by 21.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for JW (Cayman) Therapeutics Co. Ltd (2018–2024)
The table below shows the annual total assets of JW (Cayman) Therapeutics Co. Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.68 Billion | -21.70% |
| 2023-12-31 | $2.15 Billion | -23.12% |
| 2022-12-31 | $2.79 Billion | -10.44% |
| 2021-12-31 | $3.12 Billion | -17.54% |
| 2020-12-31 | $3.78 Billion | +465.27% |
| 2019-12-31 | $668.62 Million | +96.18% |
| 2018-12-31 | $340.82 Million | -- |